Partner With Us NRI

ERIS Lifesciences Ltd share Price Today

Company details

6M Return 34.48%
1Y Return 32.45%
Mkt Cap.(Cr) 11,920.38
Volume 78,788
Div Yield 0.84%
OI Chg %
Volume 78,788

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals firm Eris Lifesciences announced Q4FY23 & FY23 results:

  • Organic standalone revenue growth - 11.5% (Q4), 9.5% (FY23) & 15.6% (FY23)
  • Consolidated Revenue growth at Rs 4,028 million - 32% (Q4), 25% (FY23), and 31% (FY23)
  • Top-20 Eris mother brands accounting for 70% of revenue grew organically by 17% in FY23
  • Eris MJ (Insulin Business) organically clocks Rs 17 crore revenue in first year of commercial operations
  • Achieved organic growth of 22% in Oaknet base business after 3 flat years during FY20-FY22; full year FY23 Revenue Rs 250 crore (28% growth) with EBIDTA Rs 61 crore (margin 24.4%)
  • Amortisation of Glenmark & DRL brands has been charged for 6 months of FY23 as per statutory requirements; however financial upside from the deals has been minimal during FY23 since the deals were consummated in Q4FY23




Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

ERIS Lifesciences Ltd Stocks COMPARISION


Equity Capital: 2,195.99 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 21,819.21 39,849.27
LAST 3M 59,182.99 17,912.96
LAST 6M 101,166.54 92,564.27
LAST 12M 166,925.45 138,096.90

ERIS Lifesciences Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • ERIS Lifesciences Ltd. is an Indian company that manufactures and markets pharmaceutical products. Its manufacturing plant is located in Guwahati, Assam. It was incorporated in 2007, with its headquarters in Ahmedabad, Gujarat. The company’s total income for the September 2022 quarter was Rs 465.88 crore, up 16.04% against Rs 401.32 crore for the June 2022 quarter. On 25 October 2022, ERIS Lifesciences Ltd.’s market capitalisation stood at Rs 9,751 crore.

    The company is listed on the Bombay Stock Exchange with the code 540596 and on the National Stock Exchange with the code ERIS.

    ERIS Lifesciences Ltd. mainly focuses on cardiology, endocrinology, ENT, paediatrics, gynaecology, gastroenterology, and orthopaedics segments. It offers world-class products across these therapy segments. The company’s brands include Tendia, Tayo, Crevast, Cyblex, Glimisave, Metital, Ginkocer, and Olmin.

    On 30 September 2022, the company’s shareholding pattern showed a 52.29% promoter stake, a 15.39% FII stake, a 10.69% DII stake, and a 21.63% public stake. The leading promoter is Mr Amit Indubhushan Bakshi, the company’s founder, with a 40.27% share. During the September 2022 quarter, promoter holdings decreased from 52.30% to 52.29%, mutual fund holdings increased from 10.36% to 10.38%, and FII holdings increased from 15.35% to 15.39%.

    Mr Amit Indubhushan Bakshi is the company’s chairperson and managing director. The other team members include Mr Krishnakumar Vaidyanathan, Mr Kaushal Shah, Mr Rajeev Dalal, Mr Sachin Shah, Mr Inderjeet Singh Negi, Mr Prashant Gupta, Mr Milind Talegaonkar, Mr Vasudevan Sujesh, and Ms Kalpana Unadkat. Its auditors are Deloitte Haskins & Sells LLP. On 30 September 2022, the company had a total of 13.60 crore shares outstanding.

    On 25 October 2022, the company’s share price closed at Rs 712.10 on BSE and Rs 717.10 on NSE. The 52-week high for ERIS Lifesciences Ltd.’s shares was Rs 835, and its 52-week low was Rs 600.30. Its six-month investor return was 2.42%, and the one-year return was -12.14%.

    The company’s peers include Dr Reddys Laboratories Ltd., Cipla Ltd., Sun Pharmaceuticals Industries Ltd., and Divis Laboratories Ltd.

    As of September 2022, Franklin India Smaller Companies Fund had a 1.77% stake in the company. Aditya Birla SL Equity Hybrid Fund and L&T Midcap Fund had 1.58% and 1.29% stakes, respectively.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

8th Floor Commerce House -IV, Prahladnagar 100 FT Road, Ahmedabad, Gujarat, 380015

Tel : 91-79-30451000
Email : complianceofficer:erislifesciences.com
Website : http://www.eris.co.in

Link Intime India Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 540596
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE406M01024

FAQ’s on ERIS Lifesciences Ltd Shares

You can buy ERIS Lifesciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy ERIS Lifesciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 08, 2023 03:52 PM the closing price of ERIS Lifesciences Ltd was ₹ 876.35.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 08, 2023 03:52 PM, the market cap of ERIS Lifesciences Ltd stood at ₹ 11,920.38.

The latest PE ratio of ERIS Lifesciences Ltd as of Dec 08, 2023 03:52 PM is 30.9

The latest PB ratio of ERIS Lifesciences Ltd as of Dec 08, 2023 03:52 PM is 0.20

The 52-week high of ERIS Lifesciences Ltd is ₹ 971.90 while the 52-week low is ₹ 551.30

Download Our App

market app
market app